SteadyMed (NSDQ:STDY) said today that it submitted a new drug application to the FDA for its drug-device pulmonary arterial hypertension therapy.
The San Ramon, Calif.-based company’s lead product candidate is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.
Get the full story at our sister site, Drug Delivery Business News.
The post SteadyMed seeks FDA nod for Trevyent drug-device combo appeared first on MassDevice.